-
41.发明公开항암제에 의해 유발되는 간 독성 및 신장 독성에 대한 억제활성을 갖는 복숭아 추출물을 유효성분으로 함유하는 약학조성물 失效药物组合物，包含预防由抗癌药物引起的肝细胞毒性和抗生素毒素的麻黄素提取物
公开(公告)号：KR1020070110689A
公开(公告)日：2007-11-20
申请号：KR1020060043478
申请日：2006-05-15
Applicant: 연세대학교 산학협력단
IPC: A61K36/736 , A61P1/16
CPC classification number: A61K36/736 , A23V2200/308 , A61K2236/331 , A61K2236/333
Abstract: A pharmaceutical composition comprising the extract of Prunus persica L.(peach) for inhibiting hepatotoxicity and nephrotoxicity induced by an anticancer agent is provided to inhibit growth of cancer cells and increase anticancer effects with reducing side effects of cisplatin such as toxicity when the composition and cisplatin is simultaneously administered. A pharmaceutical composition for inhibiting hepatotoxicity and nephrotoxicity induced by an anticancer agent comprises 0.01-99 wt.%, preferably 0.02-50 wt.% of the extract of Prunus persica L. which is prepared by extracting Prunus persica L. with a solvent selected from water, C1-C4 lower alcohol or a mixed solvent thereof, wherein the Prunus persica L. is white peach or yellow peach; the daily dosage of Prunus persica L. extract is 0.0001-100 mg/kg, preferably 0.001-10 mg/kg; and the composition is formulated as tablet, pill, powder, granule, capsule, suspension, solution, emulsion or syrup.
Abstract translation: 提供包含用于抑制肝脏毒性的李子（桃）提取物和由抗癌剂引起的肾毒性的药物组合物，以抑制癌细胞的生长并增加抗癌作用，同时降低顺铂的副作用，例如当组合物和顺铂 同时给药。 用于抑制由抗癌剂诱导的肝毒性和肾毒性的药物组合物包含0.01-99重量％，优选0.02-50重量％的白芍提取物，其通过用选自以下的溶剂萃取柿子酱制备： 水，C1-C4低级醇或其混合溶剂，其中白芍是白桃或黄桃; 柿子提取物的日剂量为0.0001-100mg / kg，优选为0.001-10mg / kg; 并且组合物配制成片剂，丸剂，粉剂，颗粒剂，胶囊剂，悬浮液，溶液剂，乳剂或糖浆剂。
-
公开(公告)号：KR101957422B1
公开(公告)日：2019-03-12
申请号：KR1020180135075
申请日：2018-11-06
Applicant: 연세대학교 산학협력단 , 대한민국(농촌진흥청장)
IPC: A61K36/185 , A61K36/40 , A61K36/73
-
公开(公告)号：KR101606494B1
公开(公告)日：2016-03-28
申请号：KR1020140039551
申请日：2014-04-02
Applicant: 연세대학교 산학협력단
IPC: A61K31/4725 , A61K31/4375 , A61P19/00
Abstract: 본발명에따른연 추출물, 비스벤질이소퀴놀린계알칼로이드를유효성분으로함유하는골 질환예방및 치료용약학조성물과골 질환개선및 완화용식품조성물은세포독성이낮아안정적이며, 파골세포의형성을효과적으로억제할수 있을뿐만아니라, 형성된파골세포의골 흡수기작도효과적으로억제할수 있다.
-
公开(公告)号：KR1020150115109A
公开(公告)日：2015-10-14
申请号：KR1020140039551
申请日：2014-04-02
Applicant: 연세대학교 산학협력단
IPC: A61K31/4725 , A61K31/4375 , A61P19/00
CPC classification number: A61K31/4725 , A23L33/10 , A61K31/4748
Abstract: 본발명에따른연 추출물, 비스벤질이소퀴놀린계알칼로이드또는아포핀계알칼로이드를유효성분으로함유하는골 질환예방및 치료용약학조성물과골 질환개선및 완화용식품조성물은세포독성이낮아안정적이며, 파골세포의형성을효과적으로억제할수 있을뿐만아니라, 형성된파골세포의골 흡수기작도효과적으로억제할수 있다.
Abstract translation: 本发明涉及一种用于预防和治疗骨疾病的药物组合物，其包含Nelumbo Nucifera Gaertn提取物，双苄基异喹啉生物碱或阿扑啡碱生物碱作为活性成分。 根据本发明的用于预防和治疗骨病的食品组合物由于具有低的细胞毒性而稳定，不仅能有效抑制破骨细胞的形成，而且还能有效抑制形成的破骨细胞的骨吸收机制。
-
公开(公告)号：KR1020150115108A
公开(公告)日：2015-10-14
申请号：KR1020140039550
申请日：2014-04-02
Applicant: 연세대학교 산학협력단
IPC: A61K36/282 , A61P19/10 , A61P19/00
CPC classification number: A61K36/282 , A61K31/335 , A61K31/357
Abstract: 본발명에따른개똥쑥추출물, 아테미시닌, 또는이의유도체를유효성분으로함유하는골 질환예방및 치료용약학조성물은세포독성이낮아안정적이며, 파골세포의형성을효과적으로억제할수 있을뿐만아니라, 형성된파골세포의골 흡수기작도효과적으로억제할수 있다.
Abstract translation: 本发明涉及用于治疗和预防骨病的药物组合物，其含有蒿蒿提取物作为活性成分。 根据本发明，含有青蒿提取物，青蒿素或其衍生物作为活性成分的治疗和预防骨病的药物组合物由于具有低的细胞毒性而是稳定的，并且不仅可以有效地抑制 破骨细胞，但也可以有效抑制形成的破骨细胞的骨吸收机制。
-
Patent Agency Ranking46.发明授权
公开(公告)号：KR101282728B1
公开(公告)日：2013-07-05
申请号：KR1020100130299
申请日：2010-12-17
Applicant: 연세대학교 산학협력단 , 대한민국(농촌진흥청장)
Abstract: 본 발명은 꿩의 다리 추출물을 유효성분으로 하는 골 질환 예방 및 치료용 조성물에 관한 것이다. 본 발명에 의한 조성물은 파골세포의 형성을 감소시켜 골 흡수를 억제하며, 골다공증과 같이 뼈 골절과 관련된 골 질환 예방 및 치료효능을 가질 수 있다.
-
公开(公告)号：KR101256925B1
公开(公告)日：2013-04-19
申请号：KR1020100108245
申请日：2010-11-02
Applicant: 연세대학교 산학협력단
IPC: A61K31/015 , A61P19/10 , A61P19/00 , A61P35/00
Abstract: 본 발명은 특정 구조의 화합물을 포함하는 골 질환의 예방, 개선 또는 치료용 조성물에 관한 것이다.
본 발명의 조성물은 파골세포의 형성을 억제하여 골 질환을 예방 및 치료하는데 큰 효능을 발휘하며, 천연물(natural source)로부터 유래된 것이기 때문에 안전하다.-
公开(公告)号：KR1020120068607A
公开(公告)日：2012-06-27
申请号：KR1020100130301
申请日：2010-12-17
Applicant: 연세대학교 산학협력단 , 대한민국(농촌진흥청장)
Abstract: PURPOSE: A composition containing Rhamnus davurica Pall. Extract is provided to prevent and treat bone diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating bone diseases contains Rhamnus davurica Pall. extract as an active ingredient. The bone diseases include osteroporosis, osteromalacia, osteitis fibrosa, rachitis, or metabolic bone diseases. The extract is prepared from fruits and leaves of Rhamnus davurica Pall. A food composition for treating and relieving the bone diseases contains the extract as an active ingredient.
Abstract translation: 目的：一种含有鼠李子（Dhamurus davurica Pall）的组合物。 提供提取物以预防和治疗骨骼疾病。 构成：用于预防和治疗骨疾病的药物组合物包含鼠李子（Rhamnus davurica Pall）。 提取物作为活性成分。 骨疾病包括卵巢疏松症，卵巢软化症，纤维性纤维性骨炎，湿疹或代谢性骨病。 该提取物由Rhamnus davurica Pall的水果和叶子制备。 用于治疗和消除骨疾病的食物组合物含有提取物作为活性成分。
-
公开(公告)号：KR1020120046537A
公开(公告)日：2012-05-10
申请号：KR1020100108245
申请日：2010-11-02
Applicant: 연세대학교 산학협력단
IPC: A61K31/015 , A61P19/10 , A61P19/00 , A61P35/00
Abstract: PURPOSE: A composition containing a compound with a specific structure is provided to prevent and treat bone diseases with safety. CONSTITUTION: A pharmaceutical composition for preventing or treating bone diseases contains a compound of chemical formula 1, pharmaceutically acceptable salt thereof, solvent or hydrate thereof as an active ingredient. A food composition for preventing or treating bone diseases contains the compound of chemical formula 1 and salt, solvate, or hydrate thereof as an active ingredient. The compound is isolated from peach extract. A functional food for preventing or treating bone diseases contains the pharmaceutical composition. The functional food is powder, granules, tablets, capsules, or beverage.
Abstract translation: 目的：提供含有特定结构的化合物的组合物，以安全地预防和治疗骨病。 构成：用于预防或治疗骨疾病的药物组合物含有化学式1的化合物，其药学上可接受的盐，其溶剂或水合物作为活性成分。 用于预防或治疗骨疾病的食品组合物含有化学式1的化合物及其盐，溶剂合物或水合物作为活性成分。 该化合物与桃提取物分离。 用于预防或治疗骨疾病的功能性食品含有药物组合物。 功能性食品是粉末，颗粒，片剂，胶囊或饮料。
-
公开(公告)号：KR1020120025272A
公开(公告)日：2012-03-15
申请号：KR1020100087565
申请日：2010-09-07
Applicant: 연세대학교 산학협력단
IPC: C07D493/18 , C07H13/06 , A61K31/335 , A61P35/00
Abstract: PURPOSE: A pharmaceutical composition containing novel deoxoartemisinin-glycolipid hybrid derivatives is provided to ensure strong anti-antiangiogenic activity without cytotoxicity. CONSTITUTION: An artemisinin or deoxoartemisinin hybrid derivative is denoted by chemical formula selected from chemical formulas 1-3. A pharmaceutical composition for suppressing angiogenesis contains pharmaceutically acceptable amount of artemisinin or deoxoartemisinin-glycolipid hybrid derivatives and pharmaceutically acceptable carrier.
Abstract translation: 目的：提供含有新型脱氧青蒿素 - 糖脂混合衍生物的药物组合物，以确保无抗细胞毒性的强力抗血管生成活性。 构成：青蒿素或脱氧青蒿素杂化衍生物由选自化学式1-3的化学式表示。 用于抑制血管发生的药物组合物含有药学上可接受量的青蒿素或脱氧青蒿素 - 糖脂混合衍生物和药学上可接受的载体。
-
-
-
-
-
-
-
-
-
Search Results
60
records
(took 0.029 seconds)
